TABLE 4.
Results of the longitudinal mixed effects regression models examining CSF biomarker trajectories by follow‐up diagnosis (remain normal vs. progress to MCI/dementia)
| Outcome: Aβ42/Aβ40 | Outcome: p‐tau181 | Outcome: t‐tau | ||||
|---|---|---|---|---|---|---|
| Model predictor | Estimate (95% CI) | p‐value | Estimate (95% CI) | p‐value | Estimate (95% CI) | p‐value |
| Time | 0.018 (–0.004, 0.040) | 0.101 | 0.015 (–0.007, 0.038) | 0.176 | 0.034 (0.010, 0.057) | 0.005 |
| Time x time | –0.001 (–0.002, 0.000) | 0.092 | 0.002 (0.001, 0.003) | < 0.001 | 0.001 (0.000, 0.002) | 0.037 |
| APOE ε4 | –0.492 (–0.701, –0.284) | < 0.001 | 0.094 (–0.134, 0.322) | 0.420 | 0.051 (–0.177, 0.280) | 0.659 |
| APOE ε4 x time | –0.045 (–0.059, –0.030) | < 0.001 | 0.042 (0.022, 0.062) | < 0.001 | 0.037 (0.020, 0.054) | < 0.001 |
| Follow‐up diagnosis (progressed vs. remained normal) | –0.415 (–0.637, –0.193) | < 0.001 | 0.365 (0.122, 0.607) | 0.003 | 0.318 (0.074, 0.561) | 0.011 |
| Follow‐up diagnosis x time | –0.001 (–0.017, 0.015) | 0.883 | 0.038 (0.016, 0.060) | 0.001 | 0.023 (0.004, 0.042) | 0.019 |
Note: Different models were estimated for each CSF measure. Models were also adjusted for all variables indicated in Table 2.
Abbreviations: Aβ, amyloid beta; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; p‐tau, phosphorylated tau; t‐tau, total tau.